Difference between revisions of "SPECT Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
Line 28: Line 28:
 
==Profile Development==
 
==Profile Development==
  
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.0 post-public comments.clean copy.2017 06 26.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.1), July 01, 2017]]  
+
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.0 post-public comments.clean copy.2017 06 26.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.1), June 26, 2017]]  
  
 
*[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016]]  
 
*[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016]]  

Revision as of 15:09, 26 June 2017

Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD
Secretary: Julie Lisiecki
Roster

Project Snapshot

The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.

Under consideration:

  • quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
  • quantifying organs, like the liver, for dosimetry as potential use cases

Established Task Forces currently working toward a first Profile titled: Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease

  • Image Acquisition and Image Processing for DaTscan – Dr. Dewaraja
  • Quantitative / Image Analysis – Drs. Miyaoka and Seibyl
  • Phantoms / DRO Group – Drs. Dickson and Zimmerman
  • Clinical / Literature Review – Dr. Seibyl

Meetings/Call Summaries

Literature Review (Profile 1.0)

Profile Development

Reference Materials